• US Preventive Services Task Force, Carol M Mangione, Michael J Barry, Wanda K Nicholson, Michael Cabana, David Chelmow, Tumaini Rucker Coker, Karina W Davidson, Esa M Davis, Katrina E Donahue, Carlos Roberto Jaén, Martha Kubik, Li Li, Gbenga Ogedegbe, Lori Pbert, John M Ruiz, James Stevermer, Chien-Wen Tseng, and John B Wong.
• University of California, Los Angeles.
• JAMA. 2022 Sep 13; 328 (10): 963-967.

ImportanceThe Centers for Disease Control and Prevention estimates that 210 000 children and adolescents younger than 20 years had diabetes as of 2018; of these, approximately 23 000 had type 2 diabetes. Youth with type 2 diabetes have an increased prevalence of associated chronic comorbid conditions, including hypertension, dyslipidemia, and nonalcoholic fatty liver disease. Data indicate that the incidence of type 2 diabetes is rising; from 2002-2003 to 2014-2015, incidence increased from 9.0 cases per 100 000 children and adolescents to 13.8 cases per 100 000 children and adolescents.ObjectiveThe US Preventive Services Task Force (USPSTF) commissioned a review of the evidence on screening for prediabetes and type 2 diabetes in asymptomatic, nonpregnant persons younger than 18 years. This is a new recommendation.PopulationChildren and adolescents younger than 18 years without known diabetes or prediabetes or symptoms of diabetes or prediabetes.Evidence AssessmentThe USPSTF concludes that the evidence is insufficient to assess the balance of benefits and harms of screening for type 2 diabetes in children and adolescents. There is a lack of evidence on the effect of screening for, and early detection and treatment of, type 2 diabetes on health outcomes in youth, and the balance of benefits and harms cannot be determined.RecommendationThe USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for type 2 diabetes in children and adolescents. (I statement).

31 keywords...

hide…